Nanosized Camptothecin Conjugates for Single and Combined Drug Delivery

Chen, Kang; Sun, Yuan; Wang, Mengchi; Cheng, Xinwei

doi:10.18088/ejbmr.2.1.2016.pp8-14

Cited by 42 publications

(32 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11,12 However, for many class II drugs, reduction of particle size to the micrometer range by conventional techniques (e.g., milling) is not adequate to overcome the low bioavailability. 13,14 …”

Section: Introductionmentioning

confidence: 99%

Design and Solidification of Fast-Releasing Clofazimine Nanoparticles for Treatment of Cryptosporidiosis

et al. 2017

View full text Add to dashboard Cite

Clofazimine, a lipophilic (log P = 7.66) riminophenazine antibiotic approved by the US Food and Drug Administration (FDA) with a good safety record, was recently identified as a lead hit for cryptosporidiosis through a high-throughput phenotypic screen. Cryptosporidiosis requires fast-acting treatment as it leads to severe symptoms which, if untreated, result in morbidity for infants and small children. Consequently, a fast-releasing oral formulation of clofazimine in a water-dispersible form for pediatric administration is highly desirable. In this work, clofazimine nanoparticles were prepared with three surface stabilizers, hypromellose acetate succinate (HPMCAS), lecithin, and zein, using the flash nanoprecipitation (FNP) process. Drug encapsulation efficiencies of over 92% were achieved. Lyophilization and spray-drying were applied and optimized to produce redispersible nanoparticle powders. The release kinetics of these clofazimine nanoparticle powders in biorelevant media were measured and compared with those of crystalline clofazimine and the currently marketed formulation Lamprene. Remarkably improved dissolution rates and clofazimine supersaturation levels up to 90 times equilibrium solubility were observed with all clofazimine nanoparticles tested. Differential scanning calorimetry indicated a reduction of crystallinity of clofazimine in nanoparticles. These results strongly suggest that the new clofazimine nanoparticles prepared with affordable materials in this low-cost nanoparticle formulation process can be used as viable cryptosporidiosis therapeutics.

show abstract

Section: Introductionmentioning

confidence: 99%

Design and Solidification of Fast-Releasing Clofazimine Nanoparticles for Treatment of Cryptosporidiosis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In the medical field, the targeted ligand includes peptides, proteins, and antibodies. For better therapeutic delivery, ligands comprising of liposomes have better consistency regarding purity and binding affinity [23][24][25][26][27][28][29] . RGD peptide, which is a combination of arginine, glycine and aspartic acids, takes the responsibility to anchor the cells.…”

Section: Peptide-based Ligandmentioning

confidence: 99%

Peptide-based Drug Delivery for Curing Cancer

Huang

2019

J. Drug Delivery Ther.

View full text Add to dashboard Cite

Peptides have numerous advantages as the chains help treat cancer, tumor and several complex diseases. The review details on the different structures of peptides that can ensure actual and efficient delivery of therapy to tumor and cancer cases. The co-delivery system mainly aims to improve the therapeutic delivery process regarding manufacturing, targeting, and impact. Keywords: Nanotechnology, Peptide-based Drug Delivery, cancer

show abstract

“…Due to the unique size range of nanomedicines, they are particularly suitable for delivering anticancer drugs because of an “enhanced permeability and retention effect” (EPR) [Maeda et al, ]. The EPR effect allows nanomedicines to be selectively transported into tumor cells compared with healthy cells [Kang et al, ; Liu et al, ], thus, avoided off‐target toxicity [Kang et al, ; Han et al, ]. Nanomedicines can also enhance the solubility of delivered drugs and prolong their circulation time, which taken together can potentially improve anticancer efficacy [Nie, ].…”

Section: Introductionmentioning

confidence: 99%

RGD Peptide‐Based Target Drug Delivery of Doxorubicin Nanomedicine

Sun

Chen

Liu

et al. 2017

Drug Development Research

Self Cite

101

View full text Add to dashboard Cite

Preclinical Research Doxorubicin (DOX) is commonly used for the treatment of breast cancer and lymphoma. However, its clinical use has been severely limited due to cardiotoxicity, requiring the development of safer and more efficient pharmaceutical formulations of DOX. Advances in nanotechnology have provided new ways to administer chemotherapeutic drugs like DOX are conveyed into the body and to tumor sites. These Nanotechnology approaches have aided in the selective accumulation of DOX into tumor sites via the enhanced permeability and retention. However, the absence of active targeting ligands still hinders the effective delivery of DOX. Among all active targeting ligands developed to date, RGD peptide (Arginylglycylaspartic acid) occupies a unique position owing to its inherent safety, biocompatibility, and targeting ability. Accordingly, modification of DOX with RGD ligand is anticipated to improve transport of DOX into tumor cells. In this review, we discuss using RGD peptide for improving the therapeutic efficacy of DOX nanomedicine. Drug Dev Res 78 : 283–291, 2017. © 2017 Wiley Periodicals, Inc.

show abstract

Nanosized Camptothecin Conjugates for Single and Combined Drug Delivery

Cited by 42 publications

References 58 publications

Design and Solidification of Fast-Releasing Clofazimine Nanoparticles for Treatment of Cryptosporidiosis

Design and Solidification of Fast-Releasing Clofazimine Nanoparticles for Treatment of Cryptosporidiosis

Peptide-based Drug Delivery for Curing Cancer

RGD Peptide‐Based Target Drug Delivery of Doxorubicin Nanomedicine

Contact Info

Product

Resources

About